CPHI Korea is the Korean edition of Informa's global CPHI network, co-located with Hi (health ingredients), spanning the pharma supply chain from APIs and excipients through contract services, machinery and biopharmaceuticals. The 2026 edition expands across COEX Halls C, E and The Platz and includes a dedicated Bio Zone spotlighting Korea's biologics and biosimilars sector. Roughly 420 companies from 70+ countries exhibit to an estimated 12,000+ visitors.
Korea's biopharma base — biosimilars, cell and gene therapies, vaccines — is temperature-sensitive output, so the sourcing, CDMO and packaging deals struck here feed directly into cold-dependent manufacturing and distribution. Cold chain packaging, monitoring and pharma-logistics suppliers use it to reach Korean and wider APAC biopharma buyers and to read where regional capacity is being built. There is no formal cold chain track, but the concentration of biologics activity makes it a live adjacency.
The room is API and excipient suppliers, CDMO/CMO business development, biopharma R&D and procurement, and regulatory-affairs staff, alongside Korean and Asian manufacturers of the Samsung Biologics / Celltrion / SK bioscience profile. Government and industry bodies (Ministry of Food and Drug Safety, KoBIA) are present as partners. Seniority skews commercial and technical sourcing rather than board-level.
Be the first to raise your hand.